From images to impact: how medical imaging is reshaping clinical decision making
Each year, an estimated 340 million contrast-enhanced x-ray / computed tomography (CT) and magnetic resonance imaging (MRI) procedures are performed worldwide.[1,3] These imaging procedures play a key role in diagnoses, treatment decisions, and disease monitoring. With aging populations, rising rates of chronic diseases, greater focus on early cancer detection, and the emergence of targeted therapies, continued innovation in medical imaging is more important than ever.
Innovation can lead not only to improved detection and diagnosis of serious and life-threatening diseases, but also to meaningful shifts in how care is delivered across the treatment pathway. Key trends include advances in low-dose MRI contrast agents, a broader shift toward personalised imaging, and the growing potential of molecular imaging. Together, these developments are helping move imaging beyond diagnosis alone and toward a more precise, patient-centred role across the care pathway.
Medical imaging is no longer just about detecting disease – it is increasingly shaping how, when and for whom treatment decisions are made.
MRI contrast agents: a critical tool for diagnosis and management
For the last 30 years, gadolinium-based contrast agents (GBCAs) have been widely used in contrast-enhanced MRI to help clinicians answer critical questions about diagnosis and disease monitoring. Innovation is underway across the field to explore new options for contrast agents, reflecting an evolving clinical need. Guidance from health authorities and medical societies recommends that GBCAs be used when necessary and administered at the lowest dose required to achieve diagnostic goals.[3] This is especially relevant for patients who may require multiple contrast-enhanced MRI scans over their lifetime, including those with suspected or known cancer or other chronic diseases, and adults and children with renal impairment.
Personalised imaging
There is growing momentum behind technologies that tailor imaging protocols to the individual patient. As clinical practice moves beyond a one-size-fits-all approach, MRI is playing an increasingly important role in more personalised imaging pathways.
One example is breast cancer. Early detection is critical to reducing late-stage diagnoses and deaths, but mammography does not work equally well for all patients. Many women have dense breast tissue, which increases the risk of breast cancer and masks tumours on mammograms. Contrast-enhanced MRI and contrast-enhanced mammography can spot tumours that otherwise might be missed, and medical societies are recommending MRI for women with dense breasts.[4]
Advanced medical imaging also can support more personalised care for men with prostate cancer. Studies have shown that MRI as a first step for suspected prostate cancer can help avoid unnecessary biopsies and potential complications such as infections, minimising hospital stays and reducing further care related to false positives.[5]
Next-generation molecular imaging: addressing evolving clinical needs
Beyond dose optimisation and protocol individualisation, the next leap in imaging innovation lies in understanding disease biology through the fast-growing field of molecular imaging. As targeted therapies emerge for certain undertreated diseases, there is a growing need to detect, characterise and monitor diseases on the molecular level – beyond what anatomical imaging alone can offer. Molecular imaging complements MRI and CT by visualising biological processes in vivo, enabling earlier detection, more accurate diagnosis, and improved disease characterisation in select conditions. This shift toward visualising biology – and not just structure – is opening new possibilities for more personalised care.
One example is in cardiac amyloidosis, a frequently underdiagnosed and often fatal heart disease that affects an estimated 400,000 people worldwide.[6] Caused by the abnormal build-up of amyloid in cardiac tissue, this progressive disease is often detected late, when irreversible loss of heart function has occurred. The field is now moving towards pan-amyloid radiotracers designed to detect amyloid deposits – with the goal of supporting earlier and more accurate diagnosis.
Looking ahead to the future
As medical imaging continues to evolve, its value will increasingly be defined not by the images it produces, but by the clinical decisions it enables. Advances in low‑dose contrast agents, personalised imaging pathways and molecular imaging are shifting radiology from a primarily diagnostic discipline to an active driver of earlier, more informed and more individualised care. By providing deeper insights into disease and progression, imaging can help clinicians intervene sooner. Ultimately, the future of imaging lies in its ability to translate innovation into meaningful impact for patients along the entire treatment pathway.
References
- Healthcare in Europe: Contrast media utilisation: trends and breakthroughs. Available online: https://healthcare-in-europe.com/en/news/contrast-media-trends-breakthroughs-ecr2024.html Accessed April 2026.
2. ReadyMyMRI. How Many Medical Imaging Scans Are Done Per Year? Available online: https://readmymri.com/blog/how-many-medical-imaging-scans-are-done-per-year Accessed April 2026.
3. Springer Nature. ESR Essentials: gadolinium-wise MRI—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology. Available online: https://link.springer.com/article/10.1007/s00330-024-11214-4 Accessed April 2026.
4. Dense Breast Info. Contrast-Enhanced Mammography (CEM). Available online: https://densebreast-info.org/screening-technologies/contrast-enhanced-mammography/ Accessed April 2026
5. JAMA Network. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer. Available online: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816957 Accessed April 2026.
6. Bayer Global. Transthyretin Amyloid Cardiomyopathy. Available online: https://www.bayer.com/en/pharma/transthyretin-amyloid-cardiomyopathy Accessed April 2026.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.
